Steward Partners Investment Advisory LLC Acquires New Stake in Bristol-Myers Squibb Co (BMY)
Steward Partners Investment Advisory LLC acquired a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,010 shares of the biopharmaceutical company’s stock, valued at approximately $2,550,000.
Several other institutional investors have also added to or reduced their stakes in BMY. YHB Investment Advisors Inc. increased its position in shares of Bristol-Myers Squibb by 7.3% in the second quarter. YHB Investment Advisors Inc. now owns 61,989 shares of the biopharmaceutical company’s stock worth $3,454,000 after acquiring an additional 4,197 shares in the last quarter. Stratos Wealth Partners LTD. grew its holdings in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 321,553 shares of the biopharmaceutical company’s stock valued at $17,917,000 after purchasing an additional 2,025 shares in the last quarter. Telemus Capital LLC grew its holdings in Bristol-Myers Squibb by 14.8% during the 2nd quarter. Telemus Capital LLC now owns 8,950 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,155 shares in the last quarter. Korea Investment CORP grew its holdings in Bristol-Myers Squibb by 6.6% during the 2nd quarter. Korea Investment CORP now owns 1,141,051 shares of the biopharmaceutical company’s stock valued at $63,579,000 after purchasing an additional 70,321 shares in the last quarter. Finally, Capital Investment Advisory Services LLC acquired a new stake in Bristol-Myers Squibb during the 2nd quarter valued at $242,000. 69.70% of the stock is owned by institutional investors.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.70 on Friday. Bristol-Myers Squibb Co has a 52 week low of $51.46 and a 52 week high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The company has a market cap of $102,604.73, a price-to-earnings ratio of 20.83, a price-to-earnings-growth ratio of 1.95 and a beta of 1.09.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.
In other news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target for the company. in a report on Thursday. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating for the company in a report on Tuesday. Leerink Swann raised their price target on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a report on Tuesday. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $65.58.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.